Actuate Therapeutics’ (ACTU) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research report released on Tuesday morning, Marketbeat Ratings reports. HC Wainwright also issued estimates for Actuate Therapeutics’ Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.61) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.51) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $1.28 EPS.

A number of other brokerages also recently commented on ACTU. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, Rodman & Renshaw began coverage on shares of Actuate Therapeutics in a research note on Thursday, July 30th. They issued a “buy” rating and a $6.00 target price for the company. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.67.

Actuate Therapeutics Trading Up 16.0%

NASDAQ ACTU opened at $1.23 on Tuesday. Actuate Therapeutics has a 12 month low of $0.90 and a 12 month high of $9.22. The stock has a 50 day moving average of $1.42 and a 200-day moving average of $2.36. The company has a market cap of $29.53 million, a PE ratio of -1.41 and a beta of 0.78.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. As a group, sell-side analysts predict that Actuate Therapeutics will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Actuate Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP bought a new position in shares of Actuate Therapeutics in the second quarter valued at about $43,000. Palogic Value Management L.P. bought a new stake in shares of Actuate Therapeutics during the 2nd quarter worth about $153,000. ABS Investment Management LLC acquired a new position in Actuate Therapeutics in the 2nd quarter valued at about $111,975,000. Northwestern Mutual Wealth Management Co. acquired a new position in Actuate Therapeutics in the 2nd quarter valued at about $28,000. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in Actuate Therapeutics in the 2nd quarter valued at about $157,000.

Actuate Therapeutics News Roundup

Here are the key news stories impacting Actuate Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.61 from a loss of $0.84 and lifted its FY2027 forecast to a loss of $0.51 from a loss of $0.71. The revisions suggest the analyst expects Actuate’s losses to narrow more quickly than previously projected. HC Wainwright Reiterates Buy Rating for Actuate Therapeutics
• Positive Sentiment: Quarterly estimates were also improved: Q3 2026 EPS was raised to a loss of $0.15 from $0.21, Q4 2026 to a loss of $0.15 from $0.23, and forecasts for the first three quarters of 2027 were raised to losses of $0.13, $0.12 and $0.13, respectively.
• Positive Sentiment: The longer-term outlook strengthened materially. FY2028 EPS was raised to a loss of $0.50 from $0.75, FY2029 was upgraded to positive EPS of $0.15 from a loss of $0.07, and FY2030 was increased to $1.28 from $1.24. These projections imply a potential transition to profitability beginning in 2029.
• Neutral Sentiment: Despite the upgrades, Actuate remains expected to report losses in the near term, including a consensus full-year EPS estimate of negative $0.86. The company’s small market capitalization and biotechnology profile also leave the stock highly sensitive to clinical, financing and execution-related developments.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.